Researchers have taken an important step towards improving the diagnosis and management of prostate cancer by demonstrating that a quantitative imaging technique can accurately assess tumour ...

What is the study about? HER2-RADiCAL is investigating whether some people with HER2 positive breast cancer can safely receive less treatment after surgery. HER2 is a protein which can cause cancer to ...

What is the study about? POETIC-A is investigating whether adding a new drug alongside standard treatment reduces the chance of early breast cancer returning. Naturally occurring hormones can ...

What is the study about? STAR-TRAP investigates treatment options for prostate cancer which has grown in small areas around the body (metastatic prostate cancer). People with metastatic prostate ...

Advocacy engagement: policy and public affairs Our policy priorities Creating a sustainable funding model for research in universities Encouraging international talent to support cancer research ...

Research Data Manager: Integrative Cancer Epidemiology Email: [email protected] Location: Sutton Email: [email protected] Location: Sutton Home Research and discoveries Find a researcher ...

Scientists have discovered a key protein that could be targeted with a drug to treat the most common and aggressive form of pancreatic cancer. The findings, published in Nature, show that blocking the ...

A new AI test can pick out which men with high-risk prostate cancer that has not spread will require life-extending drug abiraterone. Scientists from The Institute of Cancer Research, London, and ...

A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for some men than the current standard PSA blood test, a new study reports. Results ...

As we enter 2026, scientists at The Institute of Cancer Research, London, share the developments expected this year that could soon change how cancer is treated – from technologies designed to deliver ...

A new immunotherapy drug has shown promise for safely treating prostate cancer, a phase I trial reports. Almost half of the patients in the trial that could be evaluated saw their tumour shrink after ...

The Institute of Cancer Research, London, works closely with trusts, foundations and charity partners who play an important part in enabling our state-of-the-art research. We recently marked a ...